relationship between throm bophilic mutations and preeclampsia: a prospective case-control study

Preeclampsia and its association with thrombophilia remain controversial, due to inconsistent results in different studies, which include different ethnic groups, selection criteria, and patient numbers. The aim of this study was to determine the relationship between thrombophilia and preeclamptic patients in our region. In a prospective case-control study, we compared 100 consecutive women with preeclampsia and eclampsia [group 1] with 100 normal pregnant women [group 2]. All women were tested two months after delivery for mutations of factor V Leiden, methylenetetrahydrofolate reductase [MTHFR], and prothrombin gene mutation as well as for deficiencies of protein C, protein S. and antithrombin III. A thrombophilic mutation was found in 42 [42%] and 28 [28%] women in group 1 and group 2, respectively [P=0.27, OR 1.5, 95%Cl 1.0-2.2]. The incidence of Factor V Leiden mutation [heterozygous], prothrombin mutation [heterozygous], prothrombin mutation [homozygous], MTHFR mutation [homozygous] was not statistically significant in group 1 compared with group 2 [P>0.05]. Also, deficiencies of protein S, protein C, and antithrombin III were not statistically significant in group 1 compared with group 2 [P>0.05]. There was no difference in thrombophilic mutations between preeclamptic patients and normal pregnant women in our region. Therefore, we suggest that preeclamptic patients should not be tested for thrombophilia

Pregnancy complicated by superior vena cava thrombosis and pulmonary embolism in a patient with behcet disease and the use of heparin for treatment

Behcet disease is a multisystemic vasculitis of unknown origin. Vascular involvement has been considered to result from systemic vasculitis, occurs in 5-10% of these patients. We report a 34-year-old pregnant woman complicated by superior vena cava thrombosis, and pulmonary embolism in a patient with Behcet disease